Navigation Links
Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses

WARSAW, Ind., May 19 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) announced today that Mark C. Throdahl has joined the Company as Group President, Global Businesses. He will have responsibility for Zimmer Spine, Zimmer Dental, Zimmer Trauma, Zimmer Orthopaedic Surgical Products, Zimmer Computer Assisted Solutions and the Human Motion Institute. Mr. Throdahl will report to David Dvorak, Zimmer Holdings President and Chief Executive Officer.

"We are delighted to have an executive of Mark's reputation and experience join our leadership team at Zimmer," said Mr. Dvorak. "A key part of our growth strategy involves investing in and expanding the businesses for which Mark will be responsible, and he is an ideal person to lead these efforts. He has a longstanding, proven track record of building medical device businesses around the world."

Mr. Throdahl most recently served as Chief Executive Officer for Consort Medical plc, a leader in medical devices for inhaled drug delivery and anesthesia, which is based in Milton Keynes, United Kingdom. Prior to joining Consort in 2001, he held various management roles at Becton Dickinson & Co. from 1988 to 2001, both at the corporate headquarters where he served as Senior Vice President and President of Drug Delivery, and in Japan, where he held the position of President, Nippon Becton Dickinson. He started his medical devices career in 1975 with Mallinckrodt Group, where he held sales and marketing positions of increasing responsibility, ultimately being named General Manager of the Critical Care business.

A graduate of Princeton University with a Bachelor of Arts (with distinction) in Economics and Russian Studies, Mr. Throdahl also holds an MBA from the Harvard Business School.

"I am excited to be joining Zimmer and to have the opportunity to focus on maximizing the potential in the outstanding stable of Zimmer global businesses," said Mr. Throdahl. "In my more than 30 years in the medical device industry, I've had a chance to experience how well regarded Zimmer is for its products and people. I'm looking forward now to helping build on that reputation by driving growth in the areas outside of reconstructive orthopaedic implants."

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is a worldwide leader in designing, developing, manufacturing and marketing orthopaedic reconstructive, spinal and trauma devices, dental implants, and related orthopaedic surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2007 sales were approximately $3.9 billion. The Company is supported by the efforts of more than 7,500 employees worldwide.

For more information about Zimmer, visit

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Deferred Prosecution Agreement through March 2009 and the Corporate Integrity Agreement through 2012, the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance, the success of our quality initiatives, the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, supply and prices of raw materials and products, customer demand for our products and services, control of costs and expenses, our ability to obtain and maintain adequate intellectual property protection, our ability to successfully integrate acquired businesses, our ability to form and implement alliances, international growth, our compliance with governmental laws and regulations affecting our U.S. and international businesses including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks, product liability and intellectual property litigation losses, reimbursement levels from third-party payors, cost-containment efforts of healthcare purchasing organizations, our ability to retain the independent agents and distributors who market our products, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Zimmer Holdings to Present at Deutsche Bank 33rd Annual Health Care Conference
2. Zimmer Holdings, Inc. Reports First Quarter Financial Results
3. Zimmer Holdings to Present at Morgan Stanley Healthcare Unplugged Conference
4. Zimmer Announces New Compliance Model
5. Zimmer Announces Actions Affecting its Ohio-based Orthopaedic Surgical Products Operation
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2008 Results
7. Zimmer Holdings to Present at Upcoming Investor Conferences
8. Zimmer to Expand Manufacturing Network
9. Zimmer Holdings to Present at Merrill Lynch Health Care Conference
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
Post Your Comments:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: